

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A03/2017 OS

DESPATCHED ON 28TH MARCH 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A68; B35, B42; Cw4, Cw17; DR4, DR18; DQ4, DQ8

				Summary of Results												
				PBL				T-Cells				B-Cells				
				12	11	12	11	39	39	39	39	33	35	34	31	
				1	6	1	0	0	6	2	0	0	31	26	6	
				11	5	11	11	39	33	37	39	33	4	8	25	
				2	3	2	3	0	0	0	0	6	4	5	8	
				8.3%	54.5%	8.3%	0.0%	0.0%	15.4%	5.1%	0.0%	0.0%	88.6%	76.5%	19.4%	
				91.7%	45.5%	91.7%	100.0%	100.0%	84.6%	94.9%	100.0%	100.0%	11.4%	23.5%	80.6%	
Consensus				Negative	Not Assessed	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
HLA Antibody Specificity (Defined By CDC)				A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	
				Without DTT				Without DTT				Without DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
101	YES	YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
112	YES			NT	NT	NT	NT									Results not conclusive
114		YES	YES					Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
116		YES	YES					Negative	Negative	Negative	Negative	Equivocal	Equivocal	Equivocal	Equivocal	Dealted delivery. Low B-cell viability
119	YES			Negative	Negative	Negative	Negative									
120		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	
128	YES			Negative	Positive	Negative	Negative									
133		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
139	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
143		YES						Negative	Negative	Negative	Negative					
145		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
147	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
154		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
157		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
159		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
162		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
163		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
169		YES	YES					Negative	Positive	Positive	Negative	Equivocal	NT	Positive	Positive	Low viability and aggregates cells that not allowed a conclusive result
181		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
186		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	
189	YES			Negative	Negative	Negative	Negative									
190		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	
193	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
194		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Equivocal	
195		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Equivocal	Cells arrives clustered in the sample
197		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	
204		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Equivocal	Equivocal	Very low B-cell viability
206		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Equivocal	Serum 4 B-cells - reaction between 2 and 4
209		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Low number of B-cells
216	YES			Positive	Negative	Negative	Negative									
223		YES	YES					Negative	Positive	Negative	Negative	NT	NT	NT	NT	Low b-cell viability
227		YES	YES					Negative	Negative	Negative	Negative	NT	Positive	NT	NT	Technical failure
229	YES															No results returned
232	YES			NT	NT	NT	NT									Samples held in customs
235	YES			Negative	NT	Negative	Negative									Serum 2 is haemolysis
238	YES	YES	YES	Negative	Positive	Positive	Equivocal	Negative	Negative	Negative	Negative	Equivocal	Positive	Positive	Positive	Serum 1 DQ6 MFI 7000 + DP6 MFI 7000
239	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
245	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
252	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
259	YES															No results returned
260		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
268		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
284		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
292		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
293		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
294		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
297		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	
321		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
351		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Serum 2 was hemolyzed

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A03/2017 OS

DESPATCHED ON 28TH MARCH 2017

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101					1	1	1	1	1	8	1	1			
112	NT	NT	NT	NT									90		
114					1	4	4	1	1	8	4	1			
116					1	1	1	1	0	0	0	0		95	30
119	1	1	1	1									90		
120					1	1	1	1	1	8	4	4		100	100
128	1	4	1	1									90		
133					-	-	-	-	-	8	8	-	95	95	95
139	1	4	1	1	1	1	1	1	1	8	8	1	80	80	80
143					1	1	1	1					90		
145					-	-	-	-	-	-	-	-	100	100	
147	1	4	1	1	1	1	1	1	1	8	8	1	100	100	100
154					1	1	1	1	1	2	1	1	99		
157					1	1	1	1	1	8	6	1		90	80
159					1	1	1	1	1	8	4	1	100	85	
162					-	-	-	-	-	8	8	-	100	100	
163					1	1	1	1	1	8	6	1	98	98	
169					1	4	4	1	Equivocal	NT	8	6	90	90	
181					1	1	1	1	2	8	8	2	95	95	
186					0	0	0	0	0	8	8	8	95	90	
189	1	1	1	1	1	1	1	1	1	1	1	1	95		
190					1	1	1	1	10	100	50	30		99	80
193	1	2	1	1	1	1	1	1	1	8	4	1	99	99	97
194					-	-	-	-	-	-	-	Equivocal			
195					2	2	2	2	2	6	6	4	85	85	
197					-	Weak	-	-	-	-	Weak	-	80	80	
204					1	4	1	1	6	8	6	6	90	50	
206					1	1	1	1	1	8	8	4	90	90	
209					1	1	1	1	1	8	6	1	90		85
216	1	1	1	1									95		
223					2	4	1	1	NT	NT	NT	NT		95	70
227					-	-	-	-	NT	8	NT	NT		90	90
229															
232					NT	NT	NT	NT							
235	1	NT	1	1									85		
238	1	4	4	2	1	1	1	1	2	8	6	4	90	90	70
239	-	++++	-	-	-	++++	-	-	-	++++	-	-	90	90	90
245	1	2	1	1	1	1	1	1	1	8	4	1	100	100	100
252	2	2-4	2	2					4	6-8	6	4	80		70
259															
260					-	-	-	-	NT	NT	NT	NT		90	10
268					1	1	1	1	1	1	1	1	95	50	
284					1	1	1	1	1	8	8	2	99	85	
292					-	-	-	-	-	8	-	-	80	30	
293					0	0	0	0	0	0	0	0	70	70	
294					0	0	0	0	0	8	8	2	100	85	
297					1	2	1	1	1	8	8	6	90	90	90
321					1	1	1	1	1	8	8	1	97	97	
351					2	2	2	1	1	2	1	1	100		

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A03/2017 OS

DESPATCHED ON 28TH MARCH 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A68; B35, B42; Cw4, Cw17; DR4, DR18; DQ4, DQ8

					Summary of Results												
					PBL				T-Cells				B-Cells				
					11	10	11	10	35	35	35	35	29	32	31	29	
					Positive	5	1	1	0	3	1	0	1	29	26	5	
					Negative	10	5	10	35	32	34	35	28	3	5	24	
					NT/Equivocal	1	2	1	1	1	1	1	5	3	4	6	
					% Positive	9.1%	50.0%	9.1%	0.0%	8.6%	2.9%	0.0%	3.4%	90.6%	83.9%	17.2%	
					% Negative	90.9%	50.0%	90.9%	100.0%	91.4%	97.1%	100.0%	96.6%	9.4%	16.1%	82.8%	
Consensus					Negative	Not Assessed	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
HLA Antibody Specificity (Defined By CDC)					A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	
					With DTT				With DTT				With DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment		Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
101	YES	YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
112	YES				NT	NT	NT	NT									Results not conclusive
114		YES	YES						Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	
116		YES	YES						Negative	Negative	Negative	Negative	Equivocal	Equivocal	Equivocal	Equivocal	Dealted delivery. Low B-cell viability
119	YES				Negative	Negative	Negative	Negative									
120		YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
133		YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
139	YES	YES	YES		Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
143		YES							Negative	Negative	Negative	Negative					
147	YES	YES	YES		Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
157		YES	YES						NT	NT	NT	NT	Negative	Positive	Positive	Negative	
159		YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
162		YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
163		YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
169		YES	YES						Negative	Positive	Positive	Negative	Equivocal	NT	Positive	Positive	Low viability and aggregates cells that not allowed a conclusive result
181		YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
186		YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	
189	YES				Negative	Negative	Negative	Negative									
190		YES	YES						Negative	Negative	Negative	Negative	NT	NT	NT	NT	High B-cell mortality
193	YES	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
194		YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Positive	Equivocal	
195		YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Cells arrives clustered in the sample
197		YES	YES						Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	
204		YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Equivocal	Equivocal	Very low B-cell viability
206		YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Serum 4 B-cells - reaction between 2 and 4
209		YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Low number of B-cells
216		YES	YES		Positive	Negative	Negative	Negative									
227	YES	YES	YES						Negative	Negative	Negative	Negative	NT	Positive	NT	NT	Technical failure
229	YES																No results returned
235	YES				Negative	NT	Negative	Negative									Serum 2 is haemolysis
238	YES	YES	YES		Negative	Positive	Positive	Equivocal	Negative	Negative	Negative	Negative	Equivocal	Positive	Positive	Positive	Serum 1 DQ6 MFI 7000 + DP6 MFI 7000
245	YES	YES	YES		Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
252	YES				Negative	Negative	Negative	Negative					Negative	Positive	Positive	Negative	
260		YES	YES						Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
262	YES	YES	YES		Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
268		YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
284		YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
292		YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
293		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
294		YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
297		YES	YES						Negative	Negative	Negative	Negative	Equivocal	Positive	Positive	Positive	
321		YES	YES						Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
351		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Heat inactivation instead of with DTT. Serum 2 was hemolyzed

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A03/2017 OS

DESPATCHED ON 28TH MARCH 2017

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101					1	1	1	1	1	8	1	1			
112	NT	NT	NT	NT									90		
114					1	4	1	1	1	8	4	1			
116					1	1	1	1	0	0	0	0		95	30
119	1	1	1	1									90		
120					1	1	1	1	1	8	4	1		100	100
133					-	-	-	-	-	8	8	-	95	95	95
139	1	4	1	1	1	1	1	1	1	8	8	1	80	80	80
143					1	1	1	1						90	
147	1	4	1	1	1	1	1	1	1	8	8	1	100	100	100
157					NT	NT	NT	NT	1	8	6	1		90	80
159					1	1	1	1	1	8	6	1		100	85
162					-	-	-	-	-	8	8	-		100	100
163					1	1	1	1	1	8	6-8	1		98	98
169					1	4	4	1	Equivocal	NT	8	6		90	90
181					1	1	1	1	2	8	6	2		95	95
186					0	0	0	0	0	8	6	6		95	90
189	1	1	1	1	1	1	1	1	1	1	1	1	95		
190					1	1	1	1	NT	NT	NT	NT		99	80
193	1	2	2	1	1	1	1	1	1	8	8	1	99	99	97
194					-	-	-	-	-	-	-	Equivocal			
195					2	2	2	2	2	6	6	4		85	85
197					-	Weak	-	-	-	-	Weak	-		80	80
204					1	1	1	1	6	8	6	6		90	50
206					1	1	1	1	1	8	8	2		90	90
209	1	1	1	1					1	8	4	1		90	85
216	4	1	1	1									95		
227					-	-	-	-	NT	8	NT	NT		90	90
229															
235	1	NT	1	1									85		
238	1	4	4	2	1	1	1	1	2	8	6	4		90	70
245	1	2	1	1	1	1	1	1	1	8	8	1	100	100	100
252	2	2-4	2	2					4	6-8	6	4		80	70
260					-	-	-	-	NT	NT	NT	NT		90	10
262	1	4	1	1	1	1	1	1	4	8	6	4	100	100	100
268					1	1	1	1	1	1	1	1		95	50
284					1	1	1	1	1	8	8	1		99	85
292					-	-	-	-	-	6	-	-		80	30
293					0	0	0	0	0	0	0	0		70	70
294					0	0	0	0	0	8	8	2		100	85
297					1	1	1	1	4	8	8	4	90	90	90
321					1	1	1	1	1	8	8	1		97	97
351					1	1	1	1	1	1	1	1	100		